Trabectedin may be a valuable treatment option for elderly patients with metastatic soft tissue sarcomas.

ABSTRACT:

Background

In the landscape of metastatic soft tissue sarcoma (mSTS) treatment, anthracyclines have shown efficacy; however, their associated toxicity imposes significant limitations, especially in frail elderly patients with mSTS who are highly susceptible to severe adverse effects. In this context, trabectedin, due to its distinct pharmacological profile and safety profile, may represent an interesting alternative being demonstrated to be active in treating mSTS. These features hold particular significance for elderly and unfit patients with mSTS, where balancing treatment benefits with potential adverse effects represents the pivotal objective.

Methods

The investigation was focused on a specific group of 11 elderly patients with mSTS aged ≥70, all undergoing first-line tr

SUBMITTER: Miolo G 

PROVIDER: S-EPMC11306058 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature